(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Former biotech CEO sued over COVID vaccine alleged insider trading - 210 Delectable Specialty Mixed drinks
- 3Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- 4The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- 5With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- AbbVie plans to build out its presence in obesity market
- Day to day Temporary Positions That Compensate Fairly in the US
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Unsold Rams May Be Less expensive Than You Suspect
- How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- Language Learning Stages: Which One Gets Your Vote?
- Instructions to Augment the Presentation of Your Kona SUV
- Key Training: Picking a Significant for Monetary Achievement
